Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Thursday, February 26, 2015
Fourth Question of the Day February 26, 2015 How long should drugs or api be studied to determine whether they do what their sponsors say they do? Is a two month study long enough? A year? When do the rules below apply and when don't they? When should they? Do consumers care about this or is it just sufficient if a company does a study for a couple of months and makes the claim that a product works? Are we as consumers just to the point where we will try anything in hopes that it will help us? No? Maybe?
Third Question of the Day February 26, 2015 How many people are coming forward reporting scams similar to the one reported on CBS, especially people who did want the compounded pain, scar, and migraine medications? How many total number of patients have received the exact same formula of these compounded medications with no changes to the formula (ie not specifically tailored to the specific patient)? What if the numbers show that compounded pain creams are prescribed and billed more than commercially available pain medications? What is the solution then?
New report explores the intrathecal pumps market that is poised is to grow at a CAGR of 4.1% from 2014 to 2020, to reach an estimated value of USD 0.26 billion in 2020
http://www.whatech.com/market-research-reports/press-release/medical/44832-new-report-explores-the-intrathecal-pumps-market-that-is-poised-is-to-grow-at-a-cagr-of-4-1-from-2014-to-2020-to-reach-an-estimated-value-of-usd-0-26-billion-in-2020
PCMA Statement on the 'Protecting the Integrity of Medicare Act' Medicare Part D Provision Will Curb Prescription Drug Fraud, Waste, and Abuse
WASHINGTON, Feb. 26, 2015 /PRNewswire-USNewswire/ -- Legislation passed today by the House Ways and Means Committee, includes a pharmacy provision to help prevent inappropriate prescriptions in Medicare Part D from crossing the pharmacy counter. TheProtecting the Integrity of Medicare Act (PIMA) of 2014, introduced by Ways and Means Health Subcommittee Chairman Kevin Brady(R-TX) and Ranking Member Jim McDermott (D-WA), recognizes the need to address the prescription drug abuse epidemic and implement the right policies, said the Pharmaceutical Care Management Association (PCMA).
"The key to stopping 'drugstore shopping' is preventing improper prescriptions from being filled in the first place," said PCMA President and CEO Mark Merritt. "This approach ensures high-quality standards at pharmacies that dispense opioids and other addictive medicines to at-risk patients."
The pharmacy program in Medicare Part D for controlled substances allows Part D plans and beneficiaries to choose a specific pharmacy from which that beneficiary would get controlled substances. The policy maintains beneficiary access to needed medications, but prevents "drugstore shopping."
Catamaran acquiring rival pharmacy benefit manager
Catamaran climbs after pharmacy benefits manager tops quarterly ...
Fox Business-9 hours agoShare
Shares of Catamaran jumped Thursday before markets opened and after the pharmacy benefits manager announced a $405 million acquisition and quarterly ...
Catamaran acquiring rival pharmacy benefit manager
Business Insurance-4 hours ago
Explore in depth (36 more articles)
BioRX, a speciality Pharmacy being bought by Diplomat Pharmacy Inc: One of Cincinnati's fastest-growing firms to be acquired in $315M deal
One of Cincinnati's fastest-growing firms to be acquired in $315M deal
BioRx, a specialty pharmacy with about 250 employees around the country, will become a subsidiary of .
Cincinnati Business Courier - 9 hours ago
US lab needed to assist steroid rules BY KATHERINE FIDLER 10:47AM 26 FEB 201
A COLLECTIVE of US breeding, racing and sales organisations, including Keeneland, Fasig-Tipton and the Commercial Consignors and Breeders Association, have issued a statement in support of the BHA's new anti-doping rules, but stressed the importance of certifying a domestic testing facility.
In a statement posted on the United States Jockey Club's website, the group wrote: "We are highly supportive of the aims of the BHA's enhanced equine anti-doping rules. The global nature of thoroughbred breeding, racing and sales relies heavily on international harmonisation of rules, particularly in the area of medication, and these new rules move all of us further down that road. more
Subscribe to:
Posts (Atom)